NM_183075.3:c.490+2487G>A
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_183075.3(CYP2U1):c.490+2487G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.388 in 151,862 control chromosomes in the GnomAD database, including 11,892 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.39 ( 11892 hom., cov: 31)
Consequence
CYP2U1
NM_183075.3 intron
NM_183075.3 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 1.56
Publications
9 publications found
Genes affected
CYP2U1 (HGNC:20582): (cytochrome P450 family 2 subfamily U member 1) This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This enzyme is a hydroxylase that metabolizes arachidonic acid, docosahexaenoic acid, and other long chain fatty acids. [provided by RefSeq, Jul 2008]
CYP2U1-AS1 (HGNC:54817): (CYP2U1 and SGMS2 antisense RNA 1)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.71).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.665 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP2U1 | NM_183075.3 | c.490+2487G>A | intron_variant | Intron 1 of 4 | ENST00000332884.11 | NP_898898.1 | ||
CYP2U1 | XM_005262717.2 | c.544+2433G>A | intron_variant | Intron 1 of 4 | XP_005262774.1 | |||
CYP2U1 | XM_005262720.2 | c.490+2487G>A | intron_variant | Intron 1 of 3 | XP_005262777.1 | |||
LOC107986298 | XR_001741784.2 | n.205-24071C>T | intron_variant | Intron 1 of 1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.388 AC: 58865AN: 151744Hom.: 11883 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
58865
AN:
151744
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.388 AC: 58902AN: 151862Hom.: 11892 Cov.: 31 AF XY: 0.397 AC XY: 29430AN XY: 74224 show subpopulations
GnomAD4 genome
AF:
AC:
58902
AN:
151862
Hom.:
Cov.:
31
AF XY:
AC XY:
29430
AN XY:
74224
show subpopulations
African (AFR)
AF:
AC:
17998
AN:
41388
American (AMR)
AF:
AC:
6761
AN:
15260
Ashkenazi Jewish (ASJ)
AF:
AC:
816
AN:
3466
East Asian (EAS)
AF:
AC:
3525
AN:
5158
South Asian (SAS)
AF:
AC:
2278
AN:
4812
European-Finnish (FIN)
AF:
AC:
4186
AN:
10524
Middle Eastern (MID)
AF:
AC:
79
AN:
294
European-Non Finnish (NFE)
AF:
AC:
22233
AN:
67942
Other (OTH)
AF:
AC:
740
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1808
3615
5423
7230
9038
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
566
1132
1698
2264
2830
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1793
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.